Amubarvimab, previously known as BRII-196 , represents a crucial advancement in biopharmaceutical development, particularly concerning its capacity to block the virus . This monoclonal agent demonstrates https://haarisyxas700943.activoblog.com/52512796/amubarvimab-a-deep-exploration-into-the-antibody-s-prospects